| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Chlorin E6 targets tumor tissues with high selectivity. Upon activation by light at specific wavelengths (typically ~660-670 nm), it generates reactive oxygen species (ROS), particularly singlet oxygen, which induces cellular damage, apoptosis, and necrosis in targeted cancer cells. It also modulates adipocyte differentiation and lipogenesis.
|
|---|---|
| ln Vitro |
In vitro, chlorin E6 (20 µM) effectively inhibits S. aureus, P. aeruginosa, and other microorganisms upon photoactivation. It shows potent photocytotoxicity against various cancer cell lines. Gold nanorod-chlorin e6 conjugates enhance fluorescence detection and PDT efficacy. It has been studied in 3T3-L1 cells for adipocyte modulation.
|
| ln Vivo |
In vivo, chlorin E6-mediated PDT demonstrates anticancer activity in tumor-bearing animal models upon laser irradiation. It has strong affinity for tumor tissues, enabling targeted photodynamic therapy with minimal damage to surrounding healthy tissue. It has been evaluated in various preclinical cancer models.
|
| Enzyme Assay |
In vitro photosensitization assays are performed by incubating cancer cells or microbial cultures with chlorin E6 at various concentrations in the dark for 1-24 h. Cells are then irradiated with a laser or LED light source at appropriate wavelength (e.g., 660 nm, 50-200 J/cm²). Cell viability is measured by MTT or LDH release assays. ROS generation is quantified using fluorescent probes (e.g., DCFH-DA).
|
| Cell Assay |
Cancer cell lines (e.g., HeLa, A549, MCF-7) are cultured in appropriate media with 10% FBS at 37°C in 5% CO₂. Cells are seeded in 96- or 24-well plates, treated with chlorin E6 at various concentrations (typically 0.1-50 µM) in the dark for 1-4 h, then irradiated with a light source. Cell viability is assessed 24 h post-irradiation by MTT assay.
|
| Animal Protocol |
In vivo PDT efficacy is evaluated in murine tumor models (e.g., subcutaneous xenografts). Chlorin E6 is administered intravenously or intratumorally. After a drug-light interval (typically 1-24 h) to allow tumor accumulation, the tumor is irradiated with a laser at 660-670 nm. Tumor size is measured serially, and tumor growth inhibition is calculated. Histological analysis assesses tumor necrosis.
|
| ADME/Pharmacokinetics |
Chlorin E6 has favorable pharmacokinetic properties for PDT, with rapid clearance from normal tissues and prolonged retention in tumor tissues. It is metabolized in the liver and excreted primarily via the biliary route. Its absorption maximum is in the red/near-infrared region (~660 nm), allowing deeper tissue penetration for light activation.
|
| Toxicity/Toxicokinetics |
Chlorin E6 exhibits low dark toxicity but significant phototoxicity upon light activation. Skin photosensitivity is a potential adverse effect, requiring patients to avoid light exposure after administration. No significant systemic toxicity has been reported at therapeutic doses in preclinical studies.
|
| References | |
| Additional Infomation |
Chlorin E6 is a member of the Chlorin family.
Chlorin E6 is a photosensitizer extensively studied for photodynamic therapy applications. It is naturally derived from chlorophyll degradation products. It has been investigated in clinical trials for various cancers, including skin, lung, and bladder cancers. Its favorable photophysical properties and tumor selectivity make it a promising PDT agent. |
| Molecular Formula |
C34H36N4O6
|
|---|---|
| Molecular Weight |
596.67
|
| Exact Mass |
596.263
|
| CAS # |
19660-77-6
|
| PubChem CID |
5479494
|
| Appearance |
Brown to black solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
1048.3±65.0 °C at 760 mmHg
|
| Flash Point |
587.8±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.643
|
| LogP |
6.73
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
44
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCC1=C(C2=CC3=C(C(=C(N3)C=C4[C@H]([C@@H](C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=O)O)CC(=O)O)CCC(=O)O)C)C)C=C)C
|
| InChi Key |
OYINILBBZAQBEV-UWJYYQICSA-N
|
| InChi Code |
InChI=1S/C34H36N4O6/c1-7-19-15(3)23-12-25-17(5)21(9-10-29(39)40)32(37-25)22(11-30(41)42)33-31(34(43)44)18(6)26(38-33)14-28-20(8-2)16(4)24(36-28)13-27(19)35-23/h7,12-14,17,21,35-36H,1,8-11H2,2-6H3,(H,39,40)(H,41,42)(H,43,44)/t17-,21-/m0/s1
|
| Chemical Name |
(17S,18S)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid
|
| Synonyms |
chlorin e6; Chlorin E6; CE6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~34.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.49 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6760 mL | 8.3798 mL | 16.7597 mL | |
| 5 mM | 0.3352 mL | 1.6760 mL | 3.3519 mL | |
| 10 mM | 0.1676 mL | 0.8380 mL | 1.6760 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA